Recent Updates
Recently added Catalysts

AD 237

Phase 2

COPD | Small molecule | Respiratory |Novartis AG|Trials Updated: May 16, 2006

AD 237 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2005

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment300

FDA Designations

No designations recorded

AD 237 clinical trials

AD 237 · 1 trial · 1 indication

Phase 2 1
NCT00242333A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPDCOPD
COMPLETED300 Analytics
PHASE2COMPLETED
A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
COPD
NCT00242333300
Unlock trial analytics

Study Endpoints

Primary Endpoints

Pulmonary function

Secondary Endpoints

Pulmonary function
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
AD 237DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites33

Inclusion Criteria: * Diagnosed with COPD, with symptoms of cough and chronic sputum production and/or dyspnea. * Post-bronchodilator FEV1 at no more than 65% and at least 30% of the predicted normal value. * Pre-bronchodilator FEV1/FVC ratio of less than 70%. * Current or ex-smokers with a smoking...

Countries:BulgariaHungaryPolandRomania
Unlock Eligibility Criteria

Competitive Landscape -COPD 92 trials

Top 11 of 14 competitors

CompanyTickerTrialsLead PhaseDrugs
GSK plc Sponsored ADRGSK8PHASE3Depemokimab, GSK5784283, GSK3862995B
AstraZeneca PLCAZN14PHASE3Tezepelumab, Breztri, Bevespi, Tozorakimab, AZD6793
Sanofi SA Sponsored ADRSNY8PHASE3Lunsekimig, SAR447537, Dupilumab
Merck & Co., Inc.MRK3PHASE3Ensifentrine, Frespaciguat
Pfizer Inc.PFE2PHASE3tilrekimig and rHuPH20, PF-07275315
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Alpha-1 MP
Upstream Bio, Inc.UPB1PHASE2Verekitug
Hoffmann-La RocheRHHBY2PHASE3Astegolimab, RO7830698
Generate Biomedicines, Inc.GENB1PHASE1GB-0895
Eli Lilly and CompanyLLY1PHASE2Brenipatide
United Therapeutics CorporationUTHR1PHASE2Tyvaso (treprostinil)
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Novartis AG (NVS)Pipeline, catalysts, financials, insiders and newsCOPD disease mapEvery company developing for COPD, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track